obesity therapeutics Archives

Representative image: GSK’s $1 billion SiranBio deal highlights how oligonucleotide therapies such as SA030 could open a new front in metabolic disease research by targeting visceral fat biology beyond conventional obesity drugs.

Pharma & Biotech

GSK’s $1bn SiranBio pact raises the stakes in extrahepatic siRNA delivery

by Pallavi Madhiraju
May 9, 2026
0 Comments

GLP-1 drugs dominate obesity. GSK is betting SiranBio’s SA030 can attack visceral fat risk from a different angle.

Pharma & Biotech

Does Rhythm Pharmaceuticals, Inc. now lead the rare neuroendocrine obesity treatment space?

by Soujanya Ravi
May 1, 2026
0 Comments

Discover how Rhythm Pharmaceuticals, Inc.’s EU approval of setmelanotide could redefine rare obesity treatment and what comes next for the market.

Eli Lilly’s $6 billion API facility in Alabama raises the bar for U.S. peptide manufacturing

Pharma & Biotech

Eli Lilly’s $6bn API plant in Alabama signals new era in U.S. peptide drug manufacturing

by Venkatesh B
December 9, 2025
0 Comments

Eli Lilly’s $6B Alabama facility will manufacture orforglipron and peptide APIs. Explore how this reshoring move could transform U.S. drug manufacturing.